The FDA approved lenacapavir (Yeztugo), a long-lasting HIV prevention drug, developed based on University of Utah biochemist Wesley Sundquist's research. Sundquist's work, dating back to the 1990s, focused on HIV's protein shell, revealing its sensitivity to changes. This led to the development of lenacapavir, which prevents the virus from entering cells. Clinical trials showed remarkable effectiveness, with zero HIV infections among over 2,000 women in South Africa and Uganda. The drug's approval is a significant step in combating the global HIV epidemic, impacting millions affected by the virus.

Prepared by Olivia Bennett and reviewed by editorial team.